Boston startups AI agents transform how pharma and biotech teams execute high-stakes work - reducing timelines from weeks to hours while maintaining full regulatory compliance
Across life sciences, the brightest minds are buried in busywork. Regulatory strategists, medical writers, quality and safety experts - people trained to bring therapies to market - are still spending most of their time formatting documents, managing version control, and stitching together fragmented tools. LogicFlo AI, the company building the AI agent workforce for life sciences, is changing that.
The Boston-based startup today announces a 2.7 million seed funding round to scale its intelligent agent platform across the pharmaceutical, biotech, and medtech industries. The round was led by Lightspeed with participation from leading healthcare and enterprise AI investors. It will fund product expansion, team growth, and deeper deployments with global life sciences organizations, including a Fortune 500 customer already under contract.
Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo represents a radically different vision for AI in regulated industries. In a space where 'move fast and break things' is a recipe for disaster, LogicFlo offers a new paradigm: move with precision. The platform gives every life sciences expert their own team of intelligent agents - AI collaborators designed to execute high-stakes, high-compliance tasks under human guidance, turning each specialist into the CEO of their own workflow.
While the rest of the world is focused on automation instead of people, we are building automation for people, said Udith Vaidyanathan, LogicFlos co-founder and CEO . LogicFlo puts experts firmly at the center. The goal is to let the brightest people in life sciences do what only they can do - drive medical science forward and help elevate standard of care.